Literature DB >> 11021358

Glucuronidation of apomorphine.

R S El-Bachá1, S Leclerc, P Netter, J Magdalou, A Minn.   

Abstract

Apomorphine, a dopaminergic receptor agonist, is largely used in the therapy of Parkinson's disease. In this study, we characterized the glucuronidation of apomorphine and other catechols in rat liver and brain microsomes, using UDP-[U-14C]glucuronic acid and separation of the glucuronides formed by a thin layer chromatographic method. rat liver microsomes glucuronidate apomorphine at a significant rate, that was increased in the presence of dithiothreitol. Two apomorphine glucuronides were separated by high pressure liquid chromatography. We showed by electrospray mass spectrometry that both products were monoglucuronides. Other catechols were also glucuronidated in liver microsomes at various rates, and among them, 4-nitrocatechol was the most efficiently conjugated. in rat brain microsomes, only 4-nitrocatechol was significantly glucuronidated, suggesting that in the liver, several uridine-diphosphate glucuronosyltransferase (UGT) isoforms participate to the conjugation of catechols. To determine which isoforms catalyze apomorphine glucuronidation, two recombinant enzymes expressed in V79 cells were used. The isoform UGT1A6 was unable to glucuronidate apomorphine, but we observed a significant activity catalyzed by the isoform UGT2B1. These results provide, to our knowledge, the first demonstration of apomorphine conjugation by recombinant UGT2B1, and the first evidence of the lack of apomorphine glucuronidation in the rat brain.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11021358     DOI: 10.1016/s0024-3205(00)00764-5

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  6 in total

1.  Glucuronidation of psilocin and 4-hydroxyindole by the human UDP-glucuronosyltransferases.

Authors:  Nenad Manevski; Mika Kurkela; Camilla Höglund; Timo Mauriala; Michael H Court; Jari Yli-Kauhaluoma; Moshe Finel
Journal:  Drug Metab Dispos       Date:  2009-12-10       Impact factor: 3.922

Review 2.  Pharmacological Insights into the Use of Apomorphine in Parkinson's Disease: Clinical Relevance.

Authors:  Manon Auffret; Sophie Drapier; Marc Vérin
Journal:  Clin Drug Investig       Date:  2018-04       Impact factor: 2.859

Review 3.  Oxidative stress in neurodegenerative diseases: mechanisms and therapeutic perspectives.

Authors:  Ailton Melo; Larissa Monteiro; Rute M F Lima; Diêgo M de Oliveira; Martins D de Cerqueira; Ramon S El-Bachá
Journal:  Oxid Med Cell Longev       Date:  2011-11-24       Impact factor: 6.543

4.  Editorial on Cerebral endothelial and glial cells are more than bricks in the Great Wall of the brain: insights into the way the blood-brain barrier actually works (celebrating the centenary of Goldman's experiments).

Authors:  Elena García-Martín; George E Barreto; José A G Agúndez; Rubem C A Guedes; Ramon S El-Bachá
Journal:  Front Cell Neurosci       Date:  2015-04-01       Impact factor: 5.505

5.  Role of IFN-γ and LPS on neuron/glial co-cultures infected by Neospora caninum.

Authors:  Erica Etelvina Viana De Jesus; Alex Barbosa Dos Santos; Catia Suse Oliveira Ribeiro; Alexandre Moraes Pinheiro; Songeli Menezes Freire; Ramon Santos El-Bachá; Silvia Lima Costa; Maria de Fatima Dias Costa
Journal:  Front Cell Neurosci       Date:  2014-10-27       Impact factor: 5.505

6.  Apomorphine Reduces A53T α-Synuclein-Induced Microglial Reactivity Through Activation of NRF2 Signalling Pathway.

Authors:  Tony Heurtaux; Melanie Kirchmeyer; Eric Koncina; Paul Felten; Lorraine Richart; Oihane Uriarte Huarte; Herve Schohn; Michel Mittelbronn
Journal:  Cell Mol Neurobiol       Date:  2021-08-20       Impact factor: 4.231

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.